{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T11:46:34Z","timestamp":1795088794380,"version":"4.10.2"},"reference-count":106,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"5","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Acquired resistance to immunomodulatory drugs (IMiD) remains a significant unmet need in the treatment landscape of multiple myeloma (MM). The cereblon (CRBN) pathway-dependent mechanisms are known to be vital contributors to IMiD resistance; however, they may account for only a small proportion. Recent research has unveiled additional mechanisms of acquired IMiD resistance that are independent of the CRBN pathway. In this review, we provide a comprehensive overview of the existing work on IMiD resistance in MM, focusing specifically on the emerging evidence of CRBN pathway-independent mechanisms. Finally, we discuss the plausible actionable strategies and outlook for IMiD-based therapies moving forward.<\/jats:p>","DOI":"10.3324\/haematol.2024.285636","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T11:03:18Z","timestamp":1732186998000},"page":"1074-1091","source":"Crossref","is-referenced-by-count":10,"title":["Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond"],"prefix":"10.3324","volume":"110","author":[{"given":"Phaik Ju","family":"Teoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mun Yee","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine","family":"Mitsiades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Gooding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"74692","doi-asserted-by":"crossref","unstructured":"Gao S, Wang S, Song Y. Novel immunomodulatory drugs and neo-substrates. Biomarker Res. 2020; 8:2.","DOI":"10.1186\/s40364-020-0182-y"},{"key":"74693","doi-asserted-by":"crossref","unstructured":"Singhal S, Mehta J, Desikan R. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999; 341(21):1565-1571.","DOI":"10.1056\/NEJM199911183412102"},{"key":"74694","doi-asserted-by":"crossref","unstructured":"Holstein SA, McCarthy PL. Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience. Drugs. 2017; 77(5):505-520.","DOI":"10.1007\/s40265-017-0689-1"},{"key":"74695","doi-asserted-by":"crossref","unstructured":"Weber DM, Chen C, Niesvizky R. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007; 357(21):2133-2142.","DOI":"10.1056\/NEJMoa070596"},{"key":"74696","doi-asserted-by":"crossref","unstructured":"van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021; 397(10272):410-427.","DOI":"10.1016\/S0140-6736(21)00135-5"},{"key":"74697","doi-asserted-by":"crossref","unstructured":"Pawlyn C, Davies FE, Kaiser MF. Primary IMiD refractory myeloma; results from 3894 patients treated in the phase III Myeloma XI study. Blood. 2016; 128(22):1144.","DOI":"10.1182\/blood.V128.22.1144.1144"},{"key":"74698","doi-asserted-by":"crossref","unstructured":"Lecat CSY, Taube JB, Wilson W. Defining unmet need following lenalidomide refractoriness: real-world evidence of outcomes in patients with multiple myeloma. Front Oncol. 2021; 11:703233.","DOI":"10.3389\/fonc.2021.703233"},{"key":"74699","doi-asserted-by":"crossref","unstructured":"Pawlyn C, Cairns D, Kaiser M. The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. Leukemia. 2020; 34(2):604-612.","DOI":"10.1038\/s41375-019-0595-5"},{"key":"74700","doi-asserted-by":"crossref","unstructured":"Pawlyn C, Schjesvold FH, Cairns DA. Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm. Blood Cancer J. 2024; 14(1):134.","DOI":"10.1038\/s41408-024-01109-4"},{"key":"74701","doi-asserted-by":"crossref","unstructured":"Kr\u00f6nke J, Udeshi ND, Narla A. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014; 343(6168):301-305.","DOI":"10.1126\/science.1244851"},{"key":"74702","doi-asserted-by":"crossref","unstructured":"Lu G, Middleton RE, Sun H. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014; 343(6168):305-309.","DOI":"10.1126\/science.1244917"},{"key":"74703","doi-asserted-by":"crossref","unstructured":"Martinez-H\u00f8yer S, Karsan A. Mechanisms of lenalidomide sensitivity and resistance. Exp Hematol. 2020; 91:22-31.","DOI":"10.1016\/j.exphem.2020.09.196"},{"key":"74704","doi-asserted-by":"crossref","unstructured":"Wang S, Li Z, Gao S. Key regulators of sensitivity to immunomodulatory drugs in cancer treatment. Biomarker Res. 2021; 9(1):43.","DOI":"10.1186\/s40364-021-00297-6"},{"key":"74705","doi-asserted-by":"crossref","unstructured":"Chen LY, Gooding S. Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma. Front Oncol. 2022; 12:1038329.","DOI":"10.3389\/fonc.2022.1038329"},{"key":"74706","doi-asserted-by":"crossref","unstructured":"Gandhi AK, Kang J, Havens CG. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol. 2014; 164(6):811-821.","DOI":"10.1111\/bjh.12708"},{"key":"74707","doi-asserted-by":"crossref","unstructured":"John LB, Ward AC. The Ikaros gene family: transcriptional regulators of hematopoiesis and immunity. Mol Immunol. 2011; 48(9-10):1272-1278.","DOI":"10.1016\/j.molimm.2011.03.006"},{"key":"74708","doi-asserted-by":"crossref","unstructured":"Kr\u00f6nke J, Fink EC, Hollenbach PW. Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS. Nature. 2015; 523(7559):183-188.","DOI":"10.1038\/nature14610"},{"key":"74709","doi-asserted-by":"crossref","unstructured":"Shaffer AL, Emre NC, Lamy L. IRF4 addiction in multiple myeloma. Nature. 2008; 454(7201):226-231.","DOI":"10.1038\/nature07064"},{"key":"74710","doi-asserted-by":"crossref","unstructured":"Jovanovi\u0107 KK, Roche-Lestienne C, Ghobrial IM, Facon T, Quesnel B, Manier S. Targeting MYC in multiple myeloma. Leukemia. 2018; 32(6):1295-1306.","DOI":"10.1038\/s41375-018-0036-x"},{"key":"74711","doi-asserted-by":"crossref","unstructured":"D\u2019Souza C, Prince HM, Neeson PJ. Understanding the role of T-cells in the antimyeloma effect of immunomodulatory drugs. Front Immunol. 2021; 12:632399.","DOI":"10.3389\/fimmu.2021.632399"},{"key":"74712","doi-asserted-by":"crossref","unstructured":"Noonan K, Rudraraju L, Ferguson A. Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. Clin Cancer Res. 2012; 18(5):1426-1434.","DOI":"10.1158\/1078-0432.CCR-11-1221"},{"key":"74713","doi-asserted-by":"crossref","unstructured":"Kr\u00e4mer I, Engelhardt M, Fichtner S. Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro. OncoImmunology. 2016; 5(5):e1139662.","DOI":"10.1080\/2162402X.2016.1139662"},{"key":"74714","doi-asserted-by":"crossref","unstructured":"Thakurta A, Pierceall WE, Amatangelo MD, Flynt E, Agarwal A. Developing next generation immunomodulatory drugs and their combinations in multiple myeloma. Oncotarget. 2021; 12(15):1555-1563.","DOI":"10.18632\/oncotarget.27973"},{"key":"74715","doi-asserted-by":"crossref","unstructured":"Corral LG, Haslett PAJ, Muller GW. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-\u03b11. J Immunol. 1999; 163(1):380-386.","DOI":"10.4049\/jimmunol.163.1.380"},{"key":"74716","doi-asserted-by":"crossref","unstructured":"Gooding S, Ansari-Pour N, Towfic F. Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. Blood. 2021; 137(2):232-237.","DOI":"10.1182\/blood.2020007081"},{"key":"74717","doi-asserted-by":"crossref","unstructured":"Kort\u00fcm KM, Mai EK, Hanafiah NH. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood. 2016; 128(9):1226-1233.","DOI":"10.1182\/blood-2016-02-698092"},{"key":"74718","doi-asserted-by":"crossref","unstructured":"Barrio S, Munawar U, Zhu YX. IKZF1\/3 and CRL4(CRBN) E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma. Haematologica. 2020; 105(5):e237-e241.","DOI":"10.3324\/haematol.2019.217943"},{"key":"74719","doi-asserted-by":"crossref","unstructured":"Gooding S, Ansari-Pour N, Kazeroun M. Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma. Blood. 2022; 140(16):1816-1821.","DOI":"10.1182\/blood.2022015909"},{"key":"74720","doi-asserted-by":"crossref","unstructured":"Zhu YX, Braggio E, Shi C-X. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011; 118(18):4771-4779.","DOI":"10.1182\/blood-2011-05-356063"},{"key":"74721","doi-asserted-by":"crossref","unstructured":"Heintel D, Rocci A, Ludwig H. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol. 2013; 161(5):695-700.","DOI":"10.1111\/bjh.12338"},{"key":"74722","doi-asserted-by":"crossref","unstructured":"Laurens EF, Inger SN, Suzana C. Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients. Haematologica. 2018; 103(8):e368-e371.","DOI":"10.3324\/haematol.2017.186601"},{"key":"74723","doi-asserted-by":"crossref","unstructured":"Barrio S, Munawar U, Zhu YX. IKZF1\/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma. Haematologica. 2020; 105(5):e237-e241.","DOI":"10.3324\/haematol.2019.217943"},{"key":"74724","doi-asserted-by":"crossref","unstructured":"Borsi E, Mazzocchetti G, Dico AF. High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients. Clin Exp Med. 2023; 23(8):5227-5239.","DOI":"10.1007\/s10238-023-01205-y"},{"key":"74725","doi-asserted-by":"crossref","unstructured":"Jones JR, Barber A, Le Bihan YV. Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs. Leukemia. 2021; 35(10):3017-3020.","DOI":"10.1038\/s41375-021-01373-4"},{"key":"74726","doi-asserted-by":"crossref","unstructured":"Bohl SR, Schmalbrock LK, Bauhuf I. Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma. Blood Adv. 2021; 5(9):2391-2402.","DOI":"10.1182\/bloodadvances.2020003541"},{"key":"74727","doi-asserted-by":"crossref","unstructured":"Weinhold N, Ashby C, Rasche L. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016; 128(13):1735-1744.","DOI":"10.1182\/blood-2016-06-723007"},{"key":"74728","doi-asserted-by":"crossref","unstructured":"Broyl A, Kuiper R, van Duin M. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood. 2013; 121(4):624-627.","DOI":"10.1182\/blood-2012-06-438101"},{"key":"74729","doi-asserted-by":"crossref","unstructured":"Dimopoulos K, Fibiger Munch-Petersen H, Winther Eskelund C. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma. Leuk Lymphoma. 2019; 60(1):180-188.","DOI":"10.1080\/10428194.2018.1466290"},{"key":"74730","doi-asserted-by":"crossref","unstructured":"Tachita T, Kinoshita S, Ri M. Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma. Cancer Science. 2020; 111(4):1333-1343.","DOI":"10.1111\/cas.14352"},{"key":"74731","doi-asserted-by":"crossref","unstructured":"Paludo J, Mikhael JR, LaPlant BR. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood. 2017; 130(10):1198-1204.","DOI":"10.1182\/blood-2017-05-782961"},{"key":"74732","doi-asserted-by":"crossref","unstructured":"Richardson PG, Oriol A, Beksac M. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019; 20(6):781-794.","DOI":"10.1016\/S1470-2045(19)30152-4"},{"key":"74733","doi-asserted-by":"crossref","unstructured":"Kr\u00f6nke J, Kuchenbauer F, Kull M. IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM). Leukemia. 2017; 31(6):1363-1367.","DOI":"10.1038\/leu.2016.384"},{"key":"74734","doi-asserted-by":"crossref","unstructured":"Pourabdollah M, Bahmanyar M, Atenafu EG, Reece D, Hou J, Chang H. High IKZF1\/3 protein expression is a favorable prognostic factor for survival of relapsed \/ refractory multiple myeloma patients treated with lenalidomide. J Hematol Oncol. 2016; 9(1):123.","DOI":"10.1186\/s13045-016-0354-2"},{"key":"74735","doi-asserted-by":"crossref","unstructured":"Zhu YX, Braggio E, Shi CX. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood. 2014; 124(4):536-545.","DOI":"10.1182\/blood-2014-02-557819"},{"key":"74736","doi-asserted-by":"crossref","unstructured":"Kalff A, Khong T, Ramachandran M. Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD). Leuk Lymphoma. 2021; 62(12):2981-2991.","DOI":"10.1080\/10428194.2021.1948030"},{"key":"74737","doi-asserted-by":"crossref","unstructured":"de Matos Simoes R, Shirasaki R, Downey-Kopyscinski SL. Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias. Nat Cancer. 2023; 4(5):754-773.","DOI":"10.1038\/s43018-023-00550-x"},{"key":"74738","doi-asserted-by":"crossref","unstructured":"Zhu YX, Shi C-X, Bruins LA. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4. Blood Cancer J. 2019; 9(2):19.","DOI":"10.1038\/s41408-019-0173-0"},{"key":"74739","doi-asserted-by":"crossref","unstructured":"Bjorklund CC, Ma W, Wang ZQ. Evidence of a role for activation of Wnt\/beta-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem. 2011; 286(13):11009-11020.","DOI":"10.1074\/jbc.M110.180208"},{"key":"74740","doi-asserted-by":"crossref","unstructured":"Bjorklund CC, Baladandayuthapani V, Lin HY. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia. 2014; 28(2):373-383.","DOI":"10.1038\/leu.2013.174"},{"key":"74741","doi-asserted-by":"crossref","unstructured":"Giesen N, Paramasivam N, Toprak UH. Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities. Haematologica. 2022; 107(8):1891-1901.","DOI":"10.3324\/haematol.2021.279360"},{"key":"74742","doi-asserted-by":"crossref","unstructured":"Pasca S, Tomuleasa C, Teodorescu P. KRAS\/NRAS\/BRAF mutations as potential targets in multiple myeloma. Front Oncol. 2019; 9:1137.","DOI":"10.3389\/fonc.2019.01137"},{"key":"74743","doi-asserted-by":"crossref","unstructured":"Perroud C, Thurian D, Andres M. Effect of MAPK activation via mutations in NRAS, KRAS and BRAF on clinical outcome in newly diagnosed multiple myeloma. Hematol Oncol. 2023; 41(5):912-921.","DOI":"10.1002\/hon.3208"},{"key":"74744","doi-asserted-by":"crossref","unstructured":"Ocio EM, Fern\u00e1ndez-L\u00e1zaro D, San-Segundo L. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. Leukemia. 2015; 29(3):705-714.","DOI":"10.1038\/leu.2014.238"},{"key":"74745","doi-asserted-by":"crossref","unstructured":"Lionetti M, Barbieri M, Todoerti K. Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation. Oncotarget. 2015; 6(27):24205-24217.","DOI":"10.18632\/oncotarget.4434"},{"key":"74746","doi-asserted-by":"crossref","unstructured":"Liu J, Hideshima T, Xing L. ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment. Sci Adv. 2021; 7(23)","DOI":"10.1126\/sciadv.abg2697"},{"key":"74747","doi-asserted-by":"crossref","unstructured":"Dimopoulos K, Gimsing P, Liang G, Gr\u00f8nb\u00e6k K, Helbo S\u00f8gaard A, Lakshminarasinham R. Cereblon is downregulated by promoter nucleosome occupancy in acquired IMiD resistance: the potential of IMiD resensitization by epigenetic therapy. Blood. 2016; 128(22):3258-3258.","DOI":"10.1182\/blood.V128.22.3258.3258"},{"key":"74748","doi-asserted-by":"crossref","unstructured":"Dimopoulos K, S\u00f8gaard Helbo A, Fibiger Munch-Petersen H. Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner. Mol Oncol. 2018; 12(2):180-195.","DOI":"10.1002\/1878-0261.12157"},{"key":"74749","doi-asserted-by":"crossref","unstructured":"Kalff A, Khong T, Mithraprabhu S. Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study). Leuk Lymphoma. 2019; 60(9):2143-2151.","DOI":"10.1080\/10428194.2019.1571201"},{"key":"74750","doi-asserted-by":"crossref","unstructured":"Khouri J, Faiman BM, Grabowski D. DNA methylation inhibition in myeloma: experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. Semin Hematol. 2021; 58(1):45-55.","DOI":"10.1053\/j.seminhematol.2020.12.004"},{"key":"74751","doi-asserted-by":"crossref","unstructured":"Alaterre E, Ovejero S, Herviou L. Comprehensive characterization of the epigenetic landscape in multiple myeloma. Theranostics. 2022; 12(4):1715-1729.","DOI":"10.7150\/thno.54453"},{"key":"74752","doi-asserted-by":"crossref","unstructured":"Mori T, Verma R, Nakamoto-Matsubara R. Low NCOR2 levels in multiple myeloma patients drive multidrug resistance via MYC upregulation. Blood Cancer J. 2021; 11(12):194.","DOI":"10.1038\/s41408-021-00589-y"},{"key":"74753","doi-asserted-by":"crossref","unstructured":"Welsh SJ, Barwick BG, Meermeier EW. Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma. Blood Cancer Discov. 2023; 5(1):34-55.","DOI":"10.1158\/2643-3230.BCD-23-0062"},{"key":"74754","doi-asserted-by":"crossref","unstructured":"Neri P, Barwick BG, Jung D. ETV4-dependent transcriptional plasticity maintains MYC expression and results in IMiD resistance in multiple myeloma. Blood Cancer Discov. 2024; 5(1):56-73.","DOI":"10.1158\/2643-3230.BCD-23-0061"},{"key":"74755","doi-asserted-by":"crossref","unstructured":"Hagen P, Zhang J, Barton K. High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions. Blood Cancer J. 2022; 12(5):83.","DOI":"10.1038\/s41408-022-00679-5"},{"key":"74756","doi-asserted-by":"crossref","unstructured":"Ansari-Pour N, Samur M, Flynt E. Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed \/ refractory myeloma. Blood. 2023; 141(6):620-633.","DOI":"10.1182\/blood.2022017010"},{"key":"74757","doi-asserted-by":"crossref","unstructured":"Panopoulou A, Cairns DA, Holroyd A. Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial. Blood. 2023; 141(14):1666-1674.","DOI":"10.1182\/blood.2022018339"},{"key":"74758","doi-asserted-by":"crossref","unstructured":"Teoh PJ, An O, Chung T-H. Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis. Blood. 2018; 132(12):1304-1317.","DOI":"10.1182\/blood-2018-02-832576"},{"key":"74759","doi-asserted-by":"crossref","unstructured":"Lazzari E, Mondala PK, Santos ND. Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma. Nat Commun. 2017; 8(1):1922.","DOI":"10.1038\/s41467-017-01890-w"},{"key":"74760","doi-asserted-by":"crossref","unstructured":"Koh MY, Chung T-H, Tang NXN. ADAR1-regulated cytoplasmic dsRNA-sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma. Blood. 2024.","DOI":"10.1016\/S2152-2650(23)01966-3"},{"key":"74761","doi-asserted-by":"crossref","unstructured":"Jakobsen T, Dahl M, Dimopoulos K, Gr\u00f8nb\u00e6k K, Kjems J, Kristensen LS. Genome-wide circular RNA expression patterns reflect resistance to immunomodulatory drugs in multiple myeloma cells. Cancers. 2021; 13(3):365.","DOI":"10.3390\/cancers13030365"},{"key":"74762","doi-asserted-by":"crossref","unstructured":"Ng YLD, Ramberger E, Bohl SR. Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma. Nat Commun. 2022; 13(1):1009.","DOI":"10.1038\/s41467-022-28515-1"},{"key":"74763","doi-asserted-by":"crossref","unstructured":"Zhan F, Huang Y, Colla S. The molecular classification of multiple myeloma. Blood. 2006; 108(6):2020-2028.","DOI":"10.1182\/blood-2005-11-013458"},{"key":"74764","doi-asserted-by":"crossref","unstructured":"Kawano Y, Fujiwara S, Wada N. Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide. Int J Oncol. 2012; 41(3):876-884.","DOI":"10.3892\/ijo.2012.1545"},{"key":"74765","doi-asserted-by":"crossref","unstructured":"Lopez-Girona A, Heintel D, Zhang L-H. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br J Haematol. 2011; 154(3):325-336.","DOI":"10.1111\/j.1365-2141.2011.08689.x"},{"key":"74766","doi-asserted-by":"crossref","unstructured":"Ferguson ID, Pati\u00f1o-Escobar B, Tuomivaara ST. The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance. Nat Commun. 2022; 13(1):4121.","DOI":"10.1038\/s41467-022-31810-6"},{"key":"74767","doi-asserted-by":"crossref","unstructured":"Arana P, Paiva B, Cedena MT. Prognostic value of antigen expression in multiple myeloma: a PETHEMA\/GEM study on 1265 patients enrolled in four consecutive clinical trials. Leukemia. 2018; 32(4):971-978.","DOI":"10.1038\/leu.2017.320"},{"key":"74768","doi-asserted-by":"crossref","unstructured":"Shim H, Ha JH, Lee H. Expression of myeloid antigen in neoplastic plasma cells is related to adverse prognosis in patients with multiple myeloma. Biomed Res Int. 2014; 2014:893243.","DOI":"10.1155\/2014\/893243"},{"key":"74769","doi-asserted-by":"crossref","unstructured":"Sievers QL, Gasser JA, Cowley GS, Fischer ES, Ebert BL. Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4(CRBN) activity. Blood. 2018; 132(12):1293-1303.","DOI":"10.1182\/blood-2018-01-821769"},{"key":"74770","doi-asserted-by":"crossref","unstructured":"Liu J, Song T, Zhou W. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity. Leukemia. 2019; 33(1):171-180.","DOI":"10.1038\/s41375-018-0205-y"},{"key":"74771","doi-asserted-by":"crossref","unstructured":"Costacurta M, Vervoort SJ, Hogg SJ, Martin BP, Johnstone RW, Shortt J. Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma. Haematologica. 2020; 106(7):2013-2017.","DOI":"10.3324\/haematol.2020.265611"},{"key":"74772","doi-asserted-by":"crossref","unstructured":"Maura F, Boyle EM, Coffey D. Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens. Nat Cancer. 2023; 4(12):1660-1674.","DOI":"10.1038\/s43018-023-00657-1"},{"key":"74773","doi-asserted-by":"crossref","unstructured":"Chen M, Zhu J, Yang X, Yao J, Liu Y, Liu Q. PD-1 and LAG-3-positive T cells are associated with clinical outcomes of relapsed \/ refractory multiple myeloma patients. Eur J Med Res. 2022; 27(1):296.","DOI":"10.1186\/s40001-022-00923-5"},{"key":"74774","doi-asserted-by":"crossref","unstructured":"Lucas F, Pennell M, Huang Y. T cell transcriptional profiling and immunophenotyping uncover LAG3 as a potential significant target of immune modulation in multiple myeloma. Biol Blood Marrow Transplant. 2020; 26(1):7-15.","DOI":"10.1016\/j.bbmt.2019.08.009"},{"key":"74775","doi-asserted-by":"crossref","unstructured":"Lee L, Alrasheed N, Khandelwal G. Increased immuneregulatory receptor expression on effector T cells as early indicators of relapse following autologous stem cell transplantation for multiple myeloma. Front Immunol. 2021; 12:618610.","DOI":"10.3389\/fimmu.2021.618610"},{"key":"74776","doi-asserted-by":"crossref","unstructured":"Wang H, Shi H, He X, Liao A. Downregulation of chemokine CCL20 involved in myeloma cells resistant to elotuzumab and lenalidomide. Onco Targets Ther. 2021; 14:2789-2795.","DOI":"10.2147\/OTT.S300328"},{"key":"74777","doi-asserted-by":"crossref","unstructured":"Chong PSY, Chooi J-Y, Lim JSL. Histone methyltransferase NSD2 activates PKC\u03b1 to drive metabolic reprogramming and lenalidomide resistance in multiple myeloma. Cancer Res. 2023; 83(20):3414-3427.","DOI":"10.1158\/0008-5472.CAN-22-3481"},{"key":"74778","doi-asserted-by":"crossref","unstructured":"Dhup S, Dadhich RK, Porporato PE, Sonveaux P. Multiple biological activities of lactic acid in cancer: influences on tumor growth, angiogenesis and metastasis. Curr Pharm Des. 2012; 18(10):1319-1330.","DOI":"10.2174\/138161212799504902"},{"key":"74779","doi-asserted-by":"crossref","unstructured":"Kuo AJ, Cheung P, Chen K. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol Cell. 2011; 44(4):609-620.","DOI":"10.1016\/j.molcel.2011.08.042"},{"key":"74780","doi-asserted-by":"crossref","unstructured":"Yamamoto T, Nakayama J, Yamamoto Y, Kuroda M, Hattori Y, Ochiya T. SORT1\/LAMP2-mediated extracellular vesicle secretion and cell adhesion are linked to lenalidomide resistance in multiple myeloma. Blood Adv. 2022; 6(8):2480-2495.","DOI":"10.1182\/bloodadvances.2021005772"},{"key":"74781","doi-asserted-by":"crossref","unstructured":"Gandhi AK, Mendy D, Waldman M. Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. Br J Haematol. 2014; 164(2):233-244.","DOI":"10.1111\/bjh.12622"},{"key":"74782","doi-asserted-by":"crossref","unstructured":"Bjorklund CC, Lu L, Kang J. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. Blood Cancer J. 2015; 5(10):e354.","DOI":"10.1038\/bcj.2015.66"},{"key":"74783","doi-asserted-by":"crossref","unstructured":"Bohl SR, Schmalbrock LK, Bauhuf I. Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma. Blood Adv. 2021; 5(9):2391-2402.","DOI":"10.1182\/bloodadvances.2020003541"},{"key":"74784","doi-asserted-by":"crossref","unstructured":"Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019; 575(7782):299-309.","DOI":"10.1038\/s41586-019-1730-1"},{"key":"74785","doi-asserted-by":"crossref","unstructured":"Moffitt JR, Lundberg E, Heyn H. The emerging landscape of spatial profiling technologies. Nat Rev Genet. 2022; 23(12):741-759.","DOI":"10.1038\/s41576-022-00515-3"},{"key":"74786","doi-asserted-by":"crossref","unstructured":"Sorin M, Rezanejad M, Karimi E. Single-cell spatial landscapes of the lung tumour immune microenvironment. Nature. 2023; 614(7948):548-554.","DOI":"10.1038\/s41586-022-05672-3"},{"key":"74787","doi-asserted-by":"crossref","unstructured":"Goh J, De Mel S, Hoppe MM. An ex vivo platform to guide drug combination treatment in relapsed \/ refractory lymphoma. Sci Transl Med. 2022; 14(667)","DOI":"10.1126\/scitranslmed.abn7824"},{"key":"74788","doi-asserted-by":"crossref","unstructured":"Rashid M, Toh TB, Hooi L. Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP). Sci Transl Med. 2018; 10(453)","DOI":"10.1126\/scitranslmed.aan0941"},{"key":"74789","doi-asserted-by":"crossref","unstructured":"Charli\u0144ski G, Vesole DH, Jurczyszyn A. Rapid progress in the use of immunomodulatory drugs and cereblon E3 ligase modulators in the treatment of multiple myeloma. Cancers (Basel). 2021; 13(18):4666.","DOI":"10.3390\/cancers13184666"},{"key":"74790","doi-asserted-by":"crossref","unstructured":"Lonial S, Popat R, Hulin C. Iberdomide (IBER) in combination with dexamethasone (DEX) in patients (pts) with relapsed \/ refractory multiple myeloma (RRMM): results from the dose-expansion phase of the CC-220-MM-001 trial. Blood. 2021; 138(Suppl 1):162.","DOI":"10.1182\/blood-2021-147704"},{"key":"74791","doi-asserted-by":"crossref","unstructured":"Matyskiela ME, Zhang W, Man HW. A cereblon modulator (CC-220) with improved degradation of Ikaros and Aiolos. J Med Chem. 2018; 61(2):535-542.","DOI":"10.1021\/acs.jmedchem.6b01921"},{"key":"74792","doi-asserted-by":"crossref","unstructured":"Richardson PG, Trudel S, Popat R. Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma. N Engl J Med. 2023; 389(11):1009-1022.","DOI":"10.1056\/NEJMoa2303194"},{"key":"74793","doi-asserted-by":"crossref","unstructured":"Lonial S, Popat R, Hulin C. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1\/2 trial. Lancet Haematol. 2022; 9(11):e822-e832.","DOI":"10.1016\/S2352-3026(22)00290-3"},{"key":"74794","doi-asserted-by":"crossref","unstructured":"Amatangelo M, Flynt E, Stong N. Pharmacodynamic changes in tumor and immune cells drive iberdomide\u2019s clinical mechanisms of activity in relapsed and refractory multiple myeloma. Cell Rep Med. 2024; 5(6):101571.","DOI":"10.1016\/j.xcrm.2024.101571"},{"key":"74795","doi-asserted-by":"crossref","unstructured":"Bird SA, Barber A, Sialana FJ. Multiomics analysis of IMiD\/ CELMoD resistant multiple myeloma models uncovers novel and targetable vulnerabilities in the SREBP lipid synthesis pathway. Blood. 2022; 140(Suppl 1):600-601.","DOI":"10.1182\/blood-2022-166444"},{"key":"74796","doi-asserted-by":"crossref","unstructured":"Chrisochoidou Y, LeBihan Y-V, Morales S. Investigating the functional impact of CRBN mutations on response to IMiD\/ celmod agents in myeloma. Blood. 2023; 142(Suppl 1):753.","DOI":"10.1182\/blood-2023-179986"},{"key":"74797","doi-asserted-by":"crossref","unstructured":"Richardson PG, San Miguel JF, Moreau P. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018; 8(11):109.","DOI":"10.1038\/s41408-018-0141-0"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11833\/77793","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11833\/78322","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11833\/77793","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:40Z","timestamp":1794046060000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":106,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285636","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,21]]}}}